PMID- 22862847
OWN - NLM
STAT- MEDLINE
DCOM- 20130702
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 1
DP  - 2013 Jan
TI  - Weight change with liraglutide and comparator therapies: an analysis of seven 
      phase 3 trials from the liraglutide diabetes development programme.
PG  - 42-54
LID - 10.1111/j.1463-1326.2012.01673.x [doi]
AB  - AIM: We investigated the relationship between weight change and related factors 
      in subjects with type 2 diabetes mellitus (T2DM) treated with liraglutide versus 
      comparator diabetes therapies. METHODS: Twenty-six-week data from seven phase 3, 
      randomized trials in the liraglutide T2DM development programme were analysed by 
      trial and treatment group: liraglutide (1.2 and 1.8 mg), active comparator and 
      placebo. Outcome measures included proportions of subjects in various weight 
      change categories and their percentage weight change from baseline; impact of 
      body mass index (BMI) and gastrointestinal (GI) adverse events (AEs) on weight 
      change and correlation of weight change with change in glycosylated haemoglobin 
      (HbA1c). RESULTS: A number of subjects experienced >5% weight loss during the 
      trials (24.4% liraglutide 1.8 mg and 17.7% liraglutide 1.2 mg; 17.7% exenatide, 
      10.0% sitagliptin, 3.6-7.0% sulphonylurea, 2.6% thiazolidinedione and 2.6% 
      glargine; 9.9% placebo). More weight loss was seen with liraglutide 1.2 and 1.8 
      mg than with active comparators except exenatide. Across trials, higher initial 
      BMI was associated with slightly greater weight loss with liraglutide. Mean 
      weight loss increased slightly the longer GI AEs persisted. Although HbA1c 
      reduction was slightly larger in higher weight loss categories across treatments 
      (including placebo), sample sizes were small and no clear correlation could be 
      determined. Liraglutide-treated subjects experienced additional HbA1c reduction 
      beyond that which appeared weight induced; thus, not all HbA1c-lowering effect 
      appears weight mediated. CONCLUSIONS: The majority of liraglutide-treated T2DM 
      subjects experienced weight loss in this analysis. Weight loss was greater and 
      occurred more in glucagon-like peptide-1 receptor agonist-treated subjects than 
      in active comparator-treated subjects.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Niswender, K
AU  - Niswender K
AD  - Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, 
      Vanderbilt University School of Medicine, Nashville, TN 37232-0475, USA. 
      kevin.niswender@vanderbilt.edu
FAU - Pi-Sunyer, X
AU  - Pi-Sunyer X
FAU - Buse, J
AU  - Buse J
FAU - Jensen, K H
AU  - Jensen KH
FAU - Toft, A D
AU  - Toft AD
FAU - Russell-Jones, D
AU  - Russell-Jones D
FAU - Zinman, B
AU  - Zinman B
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120909
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Peptides)
RN  - 0 (Pyrazines)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Triazoles)
RN  - 0 (Venoms)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9P1872D4OL (Exenatide)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Blood Glucose/*drug effects/metabolism
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Exenatide
MH  - Female
MH  - Glucagon-Like Peptide 1/*analogs & derivatives/pharmacology/therapeutic use
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/therapeutic use
MH  - Liraglutide
MH  - Male
MH  - Middle Aged
MH  - Peptides/therapeutic use
MH  - Pyrazines/therapeutic use
MH  - Sitagliptin Phosphate
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Thiazolidinediones/therapeutic use
MH  - Triazoles/therapeutic use
MH  - Venoms/therapeutic use
MH  - Weight Loss/*drug effects
EDAT- 2012/08/07 06:00
MHDA- 2013/07/03 06:00
CRDT- 2012/08/07 06:00
PHST- 2011/10/31 00:00 [received]
PHST- 2011/12/06 00:00 [revised]
PHST- 2012/07/31 00:00 [accepted]
PHST- 2012/08/07 06:00 [entrez]
PHST- 2012/08/07 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 10.1111/j.1463-1326.2012.01673.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Jan;15(1):42-54. doi: 10.1111/j.1463-1326.2012.01673.x. 
      Epub 2012 Sep 9.